Echinocandin resistance due to simultaneous FKS mutation and increased cell wall chitin in a Candida albicans bloodstream isolate following brief exposure to caspofungin

被引:22
作者
Imtiaz, Toufeeq [1 ,2 ]
Lee, Kathy K. [3 ]
Munro, Carol A. [3 ]
MacCallum, Donna M. [3 ]
Shankland, Gillian S. [4 ]
Johnson, Elizabeth M. [5 ]
MacGregor, Mark S. [1 ,2 ]
Bal, Abhijit M. [1 ,2 ]
机构
[1] Univ Hosp Crosshouse, John Lynch Renal Unit, Kilmarnock, Scotland
[2] Univ Hosp Crosshouse, Dept Microbiol, Kilmarnock, Scotland
[3] Univ Aberdeen, Sch Med Sci, Inst Med Sci, Aberdeen, Scotland
[4] Yorkhill Hosp, Dept Clin Mycol, Glasgow, Lanark, Scotland
[5] Hlth Protect Agcy, Mycol Reference Lab, Bristol, Avon, England
关键词
INTENSIVE-CARE-UNIT; INFECTIONS; MANAGEMENT; THERAPY; SOCIETY;
D O I
10.1099/jmm.0.045047-0
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
Echinocandins are first-line agents for treating severe invasive candidiasis. Glucan synthase gene (FKS1) mutations lead to echinocandin resistance but the role of enhanced chitin expression is not well recognized in clinical isolates. We report a case of bloodstream Candida albicans infection with both Fks1 hotspot mutation and elevated cell wall chitin.
引用
收藏
页码:1330 / 1334
页数:5
相关论文
共 17 条
[1]   Fitness and Virulence Costs of Candida albicans FKS1 Hot Spot Mutations Associated With Echinocandin Resistance [J].
Ben-Ami, Ronen ;
Garcia-Effron, Guillermo ;
Lewis, Russell E. ;
Gamarra, Soledad ;
Leventakos, Konstantinos ;
Perlin, David S. ;
Kontoyiannis, Dimitrios P. .
JOURNAL OF INFECTIOUS DISEASES, 2011, 204 (04) :626-635
[2]   Management of fungal infections in the intensive care unit: a survey of UK practice [J].
Chalmers, C. M. ;
Bal, A. M. .
BRITISH JOURNAL OF ANAESTHESIA, 2011, 106 (06) :827-831
[3]   FKS2 Mutations Associated with Decreased Echinocandin Susceptibility of Candida glabrata following Anidulafungin Therapy [J].
Costa-de-Oliveira, Sofia ;
Miranda, Isabel Marcos ;
Silva, Raquel M. ;
Pinto e Silva, Ana ;
Rocha, Rita ;
Amorim, Antonio ;
Rodrigues, Acacio Goncalves ;
Pina-Vaz, Cidalia .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2011, 55 (03) :1312-1314
[4]   Candida spp. with Acquired Echinocandin Resistance, France, 2004-2010 [J].
Dannaoui, Eric ;
Desnos-Ollivier, Marie ;
Garcia-Hermoso, Dea ;
Grenouillet, Frederic ;
Cassaing, Sophie ;
Baixench, Marie-Therese ;
Bretagne, Stephane ;
Dromer, Francoise ;
Lortholary, Olivier .
EMERGING INFECTIOUS DISEASES, 2012, 18 (01) :86-90
[5]   Novel FKS Mutations Associated with Echinocandin Resistance in Candida Species [J].
Garcia-Effron, Guillermo ;
Chua, Daniel Joseph ;
Tomada, Jon Rupert ;
DiPersio, Joseph ;
Perlin, David S. ;
Ghannoum, Mahmoud ;
Bonilla, Hector .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2010, 54 (05) :2225-2227
[6]   Correlating Echinocandin MIC and Kinetic Inhibition of fks1 Mutant Glucan Synthases for Candida albicans: Implications for Interpretive Breakpoints [J].
Garcia-Effron, Guillermo ;
Park, Steven ;
Perlin, David S. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2009, 53 (01) :112-122
[7]   Caspofungin-non-susceptible Candida isolates in cancer patients [J].
Kofteridis, Diamantis P. ;
Lewis, Russell E. ;
Kontoyiannis, Dimitrios P. .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2010, 65 (02) :293-295
[8]   Elevated Cell Wall Chitin in Candida albicans Confers Echinocandin Resistance In Vivo [J].
Lee, Keunsook K. ;
MacCallum, Donna M. ;
Jacobsen, Mette D. ;
Walker, Louise A. ;
Odds, Frank C. ;
Gow, Neil A. R. ;
Munro, Carol A. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2012, 56 (01) :208-217
[9]   Clinical Practice Guidelines for the Management of Candidiasis: 2009 Update by the Infectious Diseases Society of America [J].
Pappas, Peter G. ;
Kauffman, Carol A. ;
Andes, David ;
Benjamin, Daniel K., Jr. ;
Calandra, Thierry F. ;
Edwards, John E., Jr. ;
Filler, Scott G. ;
Fisher, John F. ;
Kullberg, Bart-Jan ;
Ostrosky-Zeichner, Luis ;
Reboli, Annette C. ;
Rex, John H. ;
Walsh, Thomas J. ;
Sobel, Jack D. .
CLINICAL INFECTIOUS DISEASES, 2009, 48 (05) :503-535
[10]   Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp isolates [J].
Park, S ;
Kelly, R ;
Kahn, JN ;
Robles, J ;
Hsu, MJ ;
Register, E ;
Li, W ;
Vyas, V ;
Fan, H ;
Abruzzo, G ;
Flattery, A ;
Gill, C ;
Chrebet, G ;
Parent, SA ;
Kurtz, A ;
Teppler, H ;
Douglas, CA ;
Perlin, DS .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2005, 49 (08) :3264-3273